General - Therapies
Payments companies reported to CMS as associated with General - Therapies. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with General - Therapies, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with General - Therapies
These are the largest totals companies reported as associated with General - Therapies. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Matthew Allaway | Cumberland, MD | Urology | $20,592,558.58 |
| David Dove | East Hampton, NY | Internal Medicine | $12,257,628.69 |
| Vivek Reddy | New York, NY | Clinical Cardiac Electrophysiology | $1,386,001.90 |
| Matthew Price | La Jolla, CA | Interventional Cardiology | $1,088,475.60 |
| Melissa Kong | E Palo Alto, CA | Clinical Cardiac Electrophysiology | $288,728.17 |
| Ajay Kirtane | New York, NY | Interventional Cardiology | $264,469.74 |
| Mohamed Azeem Latib | Bronx, NY | Interventional Cardiology | $263,221.28 |
| Mitul Patel | San Diego, CA | Interventional Cardiology | $210,528.71 |
| Taisei Kobayashi | Philadelphia, PA | Interventional Cardiology | $204,640.73 |
| Eric Secemsky | Boston, MA | Interventional Cardiology | $146,076.65 |
Prescribed General - Therapies?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.